Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets

Kazuki Oguri, Yuichiro Nishioka, Yoshitsugu Kobayashi, Kyoko Takahashi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Longgu (“dragon bone,” Ryu-kotsu, Fossilia Ossis Mastodi, or Os Draconis) is the only fossil crude drug listed in the Japanese Pharmacopoeia. All longgu in the current Japanese market is imported from China, where its resources are being depleted. Therefore, effective countermeasures are urgently needed to prevent resource depletion. One possible solution is the development of a substitute made from bones of contemporary animals that are closely related to the original animal source of the current longgu. However, no research has been conducted on the original animal source of longgu, except for a report on the longgu specimens present in the Shosoin Repository. Taxonomic examination was performed on the fossil specimens related to longgu which are owned by the Museum of Osaka University, Japan. In total, 20,939 fossil fragments were examined, of which 20,886 were mammalian fossils, and 246 of these fossils were classified into nine families. The longgu specimens from the Japanese market belonged to a relatively smaller variety of taxa than those from the Chinese market. Despite the variety of taxa in longgu, medical doctors using Kampo preparations with longgu have not reported any problems due to the presence of impurities in the original animal source. These results suggest that the effect of longgu is independent of its origin as long as it is closely related to the origin of the current longgu. Thus, despite the considerable effects of fossilization, our results could help in developing an optimal substitute for longgu.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Natural Medicines
DOIs
Publication statusAccepted/In press - 2017 Feb 20

Fingerprint

Tooth
Bone
Animals
Bone and Bones
Pharmaceutical Preparations
Kampo Medicine
Bone Substitutes
Museums
Pharmacopoeias
China
Japan
Impurities
Research

Keywords

  • Fossil crude drug
  • Original animal source
  • Os Draconis
  • Ryu-kotsu
  • Ryu-shi
  • Taxonomic examination

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry

Cite this

Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets. / Oguri, Kazuki; Nishioka, Yuichiro; Kobayashi, Yoshitsugu; Takahashi, Kyoko.

In: Journal of Natural Medicines, 20.02.2017, p. 1-9.

Research output: Contribution to journalArticle

@article{fbd55a54b55544fb8bbbee1d3ad703e8,
title = "Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets",
abstract = "Longgu (“dragon bone,” Ryu-kotsu, Fossilia Ossis Mastodi, or Os Draconis) is the only fossil crude drug listed in the Japanese Pharmacopoeia. All longgu in the current Japanese market is imported from China, where its resources are being depleted. Therefore, effective countermeasures are urgently needed to prevent resource depletion. One possible solution is the development of a substitute made from bones of contemporary animals that are closely related to the original animal source of the current longgu. However, no research has been conducted on the original animal source of longgu, except for a report on the longgu specimens present in the Shosoin Repository. Taxonomic examination was performed on the fossil specimens related to longgu which are owned by the Museum of Osaka University, Japan. In total, 20,939 fossil fragments were examined, of which 20,886 were mammalian fossils, and 246 of these fossils were classified into nine families. The longgu specimens from the Japanese market belonged to a relatively smaller variety of taxa than those from the Chinese market. Despite the variety of taxa in longgu, medical doctors using Kampo preparations with longgu have not reported any problems due to the presence of impurities in the original animal source. These results suggest that the effect of longgu is independent of its origin as long as it is closely related to the origin of the current longgu. Thus, despite the considerable effects of fossilization, our results could help in developing an optimal substitute for longgu.",
keywords = "Fossil crude drug, Original animal source, Os Draconis, Ryu-kotsu, Ryu-shi, Taxonomic examination",
author = "Kazuki Oguri and Yuichiro Nishioka and Yoshitsugu Kobayashi and Kyoko Takahashi",
year = "2017",
month = "2",
day = "20",
doi = "10.1007/s11418-016-1062-5",
language = "English",
pages = "1--9",
journal = "Natural Medicines",
issn = "1861-0293",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets

AU - Oguri, Kazuki

AU - Nishioka, Yuichiro

AU - Kobayashi, Yoshitsugu

AU - Takahashi, Kyoko

PY - 2017/2/20

Y1 - 2017/2/20

N2 - Longgu (“dragon bone,” Ryu-kotsu, Fossilia Ossis Mastodi, or Os Draconis) is the only fossil crude drug listed in the Japanese Pharmacopoeia. All longgu in the current Japanese market is imported from China, where its resources are being depleted. Therefore, effective countermeasures are urgently needed to prevent resource depletion. One possible solution is the development of a substitute made from bones of contemporary animals that are closely related to the original animal source of the current longgu. However, no research has been conducted on the original animal source of longgu, except for a report on the longgu specimens present in the Shosoin Repository. Taxonomic examination was performed on the fossil specimens related to longgu which are owned by the Museum of Osaka University, Japan. In total, 20,939 fossil fragments were examined, of which 20,886 were mammalian fossils, and 246 of these fossils were classified into nine families. The longgu specimens from the Japanese market belonged to a relatively smaller variety of taxa than those from the Chinese market. Despite the variety of taxa in longgu, medical doctors using Kampo preparations with longgu have not reported any problems due to the presence of impurities in the original animal source. These results suggest that the effect of longgu is independent of its origin as long as it is closely related to the origin of the current longgu. Thus, despite the considerable effects of fossilization, our results could help in developing an optimal substitute for longgu.

AB - Longgu (“dragon bone,” Ryu-kotsu, Fossilia Ossis Mastodi, or Os Draconis) is the only fossil crude drug listed in the Japanese Pharmacopoeia. All longgu in the current Japanese market is imported from China, where its resources are being depleted. Therefore, effective countermeasures are urgently needed to prevent resource depletion. One possible solution is the development of a substitute made from bones of contemporary animals that are closely related to the original animal source of the current longgu. However, no research has been conducted on the original animal source of longgu, except for a report on the longgu specimens present in the Shosoin Repository. Taxonomic examination was performed on the fossil specimens related to longgu which are owned by the Museum of Osaka University, Japan. In total, 20,939 fossil fragments were examined, of which 20,886 were mammalian fossils, and 246 of these fossils were classified into nine families. The longgu specimens from the Japanese market belonged to a relatively smaller variety of taxa than those from the Chinese market. Despite the variety of taxa in longgu, medical doctors using Kampo preparations with longgu have not reported any problems due to the presence of impurities in the original animal source. These results suggest that the effect of longgu is independent of its origin as long as it is closely related to the origin of the current longgu. Thus, despite the considerable effects of fossilization, our results could help in developing an optimal substitute for longgu.

KW - Fossil crude drug

KW - Original animal source

KW - Os Draconis

KW - Ryu-kotsu

KW - Ryu-shi

KW - Taxonomic examination

UR - http://www.scopus.com/inward/record.url?scp=85013213272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013213272&partnerID=8YFLogxK

U2 - 10.1007/s11418-016-1062-5

DO - 10.1007/s11418-016-1062-5

M3 - Article

C2 - 28220276

AN - SCOPUS:85013213272

SP - 1

EP - 9

JO - Natural Medicines

JF - Natural Medicines

SN - 1861-0293

ER -